article · Free Radical Research
extracts. Furthermore, the hepatoprotective effects of these pharmaceuticals against lead acetate-induced liver injury were evaluated in Wistar rats. Fifty adult male rats were divided into five groups. Group I, the control; Group II was subjected to oral administration of 60 mg/kg body weight (B.W) of lead acetate for one week; Groups III, IV, and V received the same initial treatment as Group II, followed by a 10-day administration of 105 mg/kg BW Immunvita, 75 mg/kg BW Immulone, or 50 mg/kg BW C-Mune, respectively. Lead acetate ingestion elevated serum levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT). Co-administration of the examined pharmaceuticals significantly mitigated the elevation of liver enzymes, demonstrating their potential for hepatoprotective effects. Serum ALT levels remained above control values after treatment, likely due to persistent hepatocyte injury or the limited duration of supplementation.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/10715762.2026.2719745
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.